Tag #Pfizer

Showing 13 to 24 of 30 results

cbsnews.com

🌐 85% Global Worthiness

May 21, 19:13

FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men

The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....

FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men

The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....

Progress

64% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors contributed to the FDA's decision to expand the warning labels on the COVID-19 vaccines?

This FDA action connects to broader concerns about vaccine safety and transparency. The increased warning for a specific demographic highlights the importance of ongoing surveillance and data analysis in vaccine safety assessments. The timing of the announcement, shortly before a Senate hearing on vaccine safety, suggests political considerations may also be at play.

theglobeandmail.com

🌐 85% Global Worthiness

May 14, 22:10

EU Court Rules Against Commission for Withholding Von der Leyen-Pfizer Texts

The European General Court ruled against the European Commission for failing to provide credible justification for withholding text messages between President Ursula von der Leyen and Pfizer CEO Albert Bourla during the COVID-19 pandemic vaccine procurement; the court decision highlights concerns ab...

EU Court Rules Against Commission for Withholding Von der Leyen-Pfizer Texts

The European General Court ruled against the European Commission for failing to provide credible justification for withholding text messages between President Ursula von der Leyen and Pfizer CEO Albert Bourla during the COVID-19 pandemic vaccine procurement; the court decision highlights concerns ab...

Progress

44% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What are the potential long-term consequences of this ruling for future EU decision-making processes and public trust in the European Commission?

The ruling's long-term impact will likely increase pressure on the EU Commission to improve its transparency practices regarding electronic communications. It may lead to changes in record-keeping policies, and further legal challenges regarding access to information are anticipated. The case sets a precedent for greater scrutiny of official communications within the EU, potentially affecting future decision-making processes and public trust.

welt.de

🌐 85% Global Worthiness

May 14, 13:15

EU Court Orders Commission to Release Von der Leyen-Pfizer Texts

The EU General Court ordered the European Commission to re-evaluate its refusal to release text messages between President Ursula von der Leyen and Pfizer CEO Albert Bourla concerning a €35 billion, 1.8 billion-dose COVID-19 vaccine contract from Spring 2021, citing insufficient justification for th...

EU Court Orders Commission to Release Von der Leyen-Pfizer Texts

The EU General Court ordered the European Commission to re-evaluate its refusal to release text messages between President Ursula von der Leyen and Pfizer CEO Albert Bourla concerning a €35 billion, 1.8 billion-dose COVID-19 vaccine contract from Spring 2021, citing insufficient justification for th...

Progress

40% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What broader issues of transparency and accountability within the European Commission does this legal case highlight, considering the context of the €35 billion vaccine deal?

This ruling highlights concerns about transparency and accountability within the European Commission's handling of major procurement contracts. The court's decision emphasizes the importance of archiving official communications, particularly those related to significant financial agreements like the Pfizer-BioNTech vaccine deal. The Commission's failure to adequately explain the absence of these text messages raises questions about potential information gaps and the need for stricter record-keeping protocols.

gr.euronews.com

🌐 85% Global Worthiness

May 14, 13:15

EU Court Rules Against Commission in Pfizer Vaccine Contract Transparency Case

The European Court of Justice ruled against the European Commission for failing to provide text messages between President von der Leyen and Pfizer CEO Bourla concerning COVID-19 vaccine contracts, as requested by The New York Times, demanding a detailed explanation for the absence of the documents.

EU Court Rules Against Commission in Pfizer Vaccine Contract Transparency Case

The European Court of Justice ruled against the European Commission for failing to provide text messages between President von der Leyen and Pfizer CEO Bourla concerning COVID-19 vaccine contracts, as requested by The New York Times, demanding a detailed explanation for the absence of the documents.

Progress

40% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What are the immediate implications of the European Court of Justice's ruling on the European Commission's handling of transparency requests regarding Pfizer vaccine contracts?

The European Court of Justice ruled that the European Commission failed to adequately justify its inability to provide text messages between Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla regarding COVID-19 vaccine contracts, as requested by The New York Times. The court found the Commission's claim of lacking the documents insufficient, demanding a credible explanation for their absence. This decision stems from a transparency dispute regarding the Pfizer vaccine contracts.

dailymail.co.uk

🌐 85% Global Worthiness

Mar 28, 01:14

UK Drug Gang Jailed for Selling Millions of Fake Xanax Pills

Brian Pitts and Katie Harlow, leaders of a UK drug gang, were jailed for producing and selling millions of fake Xanax pills internationally via the dark web and cryptocurrency, generating at least £4 million in profits, following a five-year Pfizer-led investigation.

UK Drug Gang Jailed for Selling Millions of Fake Xanax Pills

Brian Pitts and Katie Harlow, leaders of a UK drug gang, were jailed for producing and selling millions of fake Xanax pills internationally via the dark web and cryptocurrency, generating at least £4 million in profits, following a five-year Pfizer-led investigation.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What role did cryptocurrency and the dark web play in facilitating the gang's international drug trafficking operation?

The gang's sophisticated operation involved industrial-scale production in the West Midlands, utilizing pill press machines and imported ingredients from China. Distribution was facilitated through the dark web, minimizing detection and maximizing profit margins. The scale of the operation, coupled with the dangerous nature of the counterfeit pills, underscores the significant public health threat posed by such criminal enterprises.

cnbc.com

🌐 75% Global Worthiness

Feb 5, 01:10

MAI Capital Management Highlights Pfizer, Airbus, and Domino's as Promising Non-Tech Stocks

Chris Grisanti of MAI Capital Management recommended Pfizer, Airbus, and Domino's as strong non-tech stock picks, citing Pfizer's low P/E ratio and dividend yield, Airbus's position in a growing industry, and Domino's recent positive performance.

MAI Capital Management Highlights Pfizer, Airbus, and Domino's as Promising Non-Tech Stocks

Chris Grisanti of MAI Capital Management recommended Pfizer, Airbus, and Domino's as strong non-tech stock picks, citing Pfizer's low P/E ratio and dividend yield, Airbus's position in a growing industry, and Domino's recent positive performance.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What potential risks or challenges could impact the future performance of these three companies, and how might these risks be mitigated?

The selection of these three stocks suggests a strategy focusing on established companies in stable, yet growing industries, less susceptible to rapid tech market fluctuations. Pfizer's potential performance is tied to political developments, highlighting the influence of regulatory changes on the pharmaceutical sector. Airbus's success will depend on consistent execution and maintaining its competitive edge against Boeing. Domino's future performance will depend on sustained positive same-store sales.

cnn.com

🌐 85% Global Worthiness

May 16, 04:10

House Judiciary Committee Investigates Alleged Pfizer Vaccine Delay

The House Judiciary Committee is investigating allegations that Pfizer delayed its Covid-19 vaccine announcement until after the 2020 election, based on a former Pfizer executive's statements to GSK, which Pfizer denies, asserting that the process was driven by science and FDA guidelines.

House Judiciary Committee Investigates Alleged Pfizer Vaccine Delay

The House Judiciary Committee is investigating allegations that Pfizer delayed its Covid-19 vaccine announcement until after the 2020 election, based on a former Pfizer executive's statements to GSK, which Pfizer denies, asserting that the process was driven by science and FDA guidelines.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the alleged delay in clinical testing potentially impact public health outcomes and vaccine distribution?

This investigation highlights the political scrutiny surrounding the Covid-19 vaccine rollout. The timing of Pfizer's announcement, nearly a week after the election, fueled speculation of political interference. GSK's relayed account of a former Pfizer executive expressing concern about a potential investigation by the Trump administration further complicates the narrative.

euronews.com

🌐 85% Global Worthiness

May 14, 22:10

EU Court Rules Against Commission for Lack of Transparency in Pfizer Vaccine Contract Documents

The EU General Court ruled against the European Commission for failing to provide sufficient justification for not possessing text messages between President von der Leyen and Pfizer CEO Bourla concerning COVID-19 vaccine contracts, emphasizing the importance of transparency and accountability in pu...

EU Court Rules Against Commission for Lack of Transparency in Pfizer Vaccine Contract Documents

The EU General Court ruled against the European Commission for failing to provide sufficient justification for not possessing text messages between President von der Leyen and Pfizer CEO Bourla concerning COVID-19 vaccine contracts, emphasizing the importance of transparency and accountability in pu...

Progress

20% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

How does this ruling relate to broader concerns about transparency and accountability in EU decision-making processes?

The ruling reinforces the importance of transparency and accountability in public institutions, particularly concerning decisions with significant public health implications. The court's decision connects to broader concerns about the influence of commercial interests on public policy and the need for greater scrutiny of government actions. The case underscores the limitations of claiming document non-existence without credible explanation.

welt.de

🌐 85% Global Worthiness

May 14, 13:15

EU Court Orders Release of Von der Leyen-Bourla Texts on €35 Billion Vaccine Deal

The EU General Court ordered the release of text messages between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla regarding a €35 billion COVID-19 vaccine deal, after deeming the Commission's claim of not possessing them implausible.

EU Court Orders Release of Von der Leyen-Bourla Texts on €35 Billion Vaccine Deal

The EU General Court ordered the release of text messages between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla regarding a €35 billion COVID-19 vaccine deal, after deeming the Commission's claim of not possessing them implausible.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the EU court's decision on the transparency of EU-Pharma deals?

The European Union's General Court ruled that the European Commission must release text messages between Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla concerning a €35 billion vaccine deal. The court found the Commission's claim of not possessing the messages implausible, deeming their refusal to release them unlawful. This decision is not yet final.

nrc.nl

🌐 85% Global Worthiness

May 14, 01:10

EU Court Rules on "Pfizergate," Impacting Transparency and Accountability

The European Court of Justice ruled on the "Pfizergate" controversy, focusing on the possible deletion of text messages between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla concerning a €1.8 billion vaccine contract signed in 2021, raising questions about EU transparency...

EU Court Rules on "Pfizergate," Impacting Transparency and Accountability

The European Court of Justice ruled on the "Pfizergate" controversy, focusing on the possible deletion of text messages between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla concerning a €1.8 billion vaccine contract signed in 2021, raising questions about EU transparency...

Progress

56% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What are the implications of the European Court of Justice's ruling in the "Pfizergate" case for EU transparency and accountability?

The European Court of Justice ruled on the "Pfizergate" case, concerning the deletion of text messages between EU Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla regarding a €1.8 billion vaccine contract. The court's decision impacts EU transparency rules and the accessibility of official communications. Von der Leyen's actions have raised questions about accountability and the archiving of digital communications within the EU.

forbes.com

🌐 75% Global Worthiness

Mar 6, 13:14

Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns

Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.

Moderna Stock Surges on Patent Win, but Weak Financials Raise Concerns

Moderna's stock jumped 16% after winning a patent infringement case against BioNTech and Pfizer, but its weak recent financial performance, including a 66% quarterly revenue drop and negative operating margins, raises concerns for investors despite a strong balance sheet.

Progress

60% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

Given Moderna's current financial state and market volatility, what are the potential long-term risks and opportunities for investors?

While Moderna boasts a strong balance sheet with low debt and high cash reserves, its weak operating performance and negative profit margins (-123.3% operating margin) cast doubt on its long-term sustainability. The company's resilience during past market downturns has been mixed, offering limited assurance of future performance.

cnbc.com

🌐 85% Global Worthiness

Feb 4, 16:11

Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success

Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.

Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success

Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key factors driving Pfizer's exceeding fourth-quarter expectations, and what are the immediate implications for the company?

Pfizer exceeded fourth-quarter expectations, reporting adjusted earnings per share of $0.63 compared to the anticipated $0.46 and revenue of $17.76 billion against the projected $17.36 billion. This success stemmed from robust Covid product sales and effective cost-cutting measures, resulting in a $410 million net income compared to a $3.37 billion net loss in Q4 2022.

Showing 13 to 24 of 30 results